## Edwin E Zvartau

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4118329/publications.pdf

Version: 2024-02-01

126901 149686 3,595 124 33 citations h-index papers

g-index 134 134 134 3406 docs citations times ranked citing authors all docs

56

#	Article	IF	CITATIONS
1	Association Between Alcoholism and ??-Amino Butyric Acid ??2 Receptor Subtype in a Russian Population. Alcoholism: Clinical and Experimental Research, 2005, 29, 493-498.	2.4	188
2	Association between two $\hat{A}\mu$ -opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Molecular Genetics, 2006, 15, 807-819.	2.9	155
3	Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology, 2005, 49, 167-178.	4.1	126
4	Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. Archives of General Psychiatry, 2012, 69, 973.	12.3	115
5	Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal of Psychiatry, 2007, 164, 519-523.	7.2	106
6	Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136008-???.	2.4	103
7	$\hat{I}^2$ -Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. European Journal of Pharmacology, 1997, 321, 265-271.	3.5	101
8	Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1992, 41, 497-500.	2.9	96
9	Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2004, 26, 285-294.	2.8	96
10	Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2006, 31, 319-328.	2.8	95
11	Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available. Current Psychiatry Reports, 2010, 12, 448-453.	4.5	95
12	mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology, 2007, 52, 263-269.	4.1	91
13	Sweet liking and family history of alcoholism in hospitalized alcoholic and non-alcoholic patients. Alcohol and Alcoholism, 2001, 36, 165-170.	1.6	90
14	Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug and Alcohol Dependence, 2007, 90, 25-38.	3.2	86
15	Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. American Journal of Drug and Alcohol Abuse, 2016, 42, 614-620.	2.1	77
16	Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. European Neuropsychopharmacology, 2005, 15, 219-225.	0.7	75
17	Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology, 1995, 119, 92-98.	3.1	72
18	Strain differences in the analgesic and reinforcing action of morphine in mice. Pharmacology Biochemistry and Behavior, 1995, 50, 17-21.	2.9	64

#	Article	IF	CITATIONS
19	Double jeopardy-drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial. Substance Abuse Treatment, Prevention, and Policy, 2012, 7, 1.	2.2	61
20	Intravenous self-administration of abused solvents and anesthetics in mice. European Journal of Pharmacology, 2004, 485, 211-218.	3.5	57
21	Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. European Journal of Pharmacology, 1994, 264, 233-239.	3.5	56
22	Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sciences, 1997, 60, PL257-PL264.	4.3	51
23	Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1995, 52, 271-274.	2.9	50
24	Effects of N -methyl-d-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behavioural Pharmacology, 2000, 11, 37-44.	1.7	46
25	Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug and Alcohol Dependence, 2005, 79, 251-256.	3.2	46
26	Co-Morbidity of Infectious and Addictive Diseases in St. Petersburg and the Leningrad Region, Russia. European Addiction Research, 2006, 12, 12-19.	2.4	46
27	Caffeine place conditioning in rats: comparison with cocaine and ethanol. European Neuropsychopharmacology, 1998, 8, 287-291.	0.7	45
28	Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. European Neuropsychopharmacology, 1999, 9, 377-383.	0.7	44
29	Alcohol Use in Pregnant and Nonpregnant Russian Women. Alcoholism: Clinical and Experimental Research, 2007, 31, 299-307.	2.4	42
30	Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology, 2008, 196, 211-220.	3.1	42
31	Gender Differences in Neurocognitive Functioning Among Alcohol-Dependent Russian Patients. Alcoholism: Clinical and Experimental Research, 2007, 31, 745-754.	2.4	38
32	Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neuroscience and Biobehavioral Reviews, 2001, 25, 343-353.	6.1	36
33	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183.	4.1	35
34	<scp>HERMITAGE</scp> â€"a randomized controlled trial to reduce sexually transmitted infections and <scp>HIV</scp> risk behaviors among <scp>HIV</scp> â€infected <scp>R</scp> ussian drinkers. Addiction, 2015, 110, 80-90.	3.3	35
35	Enhancement of morphine self-administration in drug naive, inbred strains of mice by acute emotional stress. European Neuropsychopharmacology, 1996, 6, 63-68.	0.7	34
36	Naltrexone with or without guanfacine for preventing relapse to opiate addiction in StPetersburg, Russia. Drug and Alcohol Dependence, 2013, 132, 674-680.	3.2	34

#	Article	IF	CITATIONS
37	The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence. HIV Medicine, 2004, 5, 30-33.	2.2	33
38	Experimental estimation of addictive potential of a mixture of organic solvents. European Neuropsychopharmacology, 1994, 4, 111-118.	0.7	31
39	Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca2+ channel modulators. European Journal of Pharmacology, 1996, 295, 19-25.	3.5	31
40	Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. European Journal of Pharmacology, 2000, 390, 303-311.	3.5	31
41	Syphilis among intravenous drug-using population: epidemiological situation in St Petersburg, Russia. International Journal of STD and AIDS, 2002, 13, 618-623.	1.1	30
42	Prolongation of morphine analgesia by competitive NMDA receptor antagonist d-CPPene (SDZ EAA 494) in rats. European Journal of Pharmacology, 1998, 351, 299-305.	3.5	29
43	Caffeine, acting on adenosine $A(1)$ receptors, prevents the extinction of cocaine-seeking behavior in mice. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 535-42.	2.5	29
44	Intraaccumbens administration of NMDA receptor antagonist $(\hat{A}\pm)$ -CPP prevents locomotor activation conditioned by morphine and amphetamine in rats. Pharmacology Biochemistry and Behavior, 1996, 55, 203-207.	2.9	28
45	Overcoming opioid blockade from depot naltrexone (Prodetoxon $\hat{A}^{ extstyle  extstyl$	3.3	28
46	Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 86-92.	1.2	28
47	Effects of morphine on formalin-induced nociception in rats. European Journal of Pharmacology, 2003, 462, 109-113.	3.5	27
48	Nicotine exposure throughout early development promotes nicotine self-administration in adolescent mice and induces long-lasting behavioural changes. European Journal of Pharmacology, 2010, 640, 87-93.	3.5	26
49	Simple methodology of assessment of analgesics' addictive potential in mice. Pharmacology Biochemistry and Behavior, 1991, 39, 873-876.	2.9	24
50	Analgesic and reinforcing effects of morphine in mice. Influence of Bay K-8644 and nimodipine. Brain Research, 1994, 652, 1-8.	2.2	24
51	Facilitation of electrical brain self-stimulation behavior by abused solvents. Pharmacology Biochemistry and Behavior, 2003, 75, 199-208.	2.9	24
52	Endogenous digitalis-like ligands of the sodium pump: possible involvement in mood control and ethanol addiction. European Neuropsychopharmacology, 2002, 12, 1-12.	0.7	23
53	Mutation screen of theGAD2 gene and association study of alcoholism in three populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 183-192.	1.7	23
54	Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology, 2018, 235, 1955-1965.	3.1	23

#	Article	IF	CITATIONS
55	Isradipine is able to separate morphine-induced analgesia and place conditioning. Brain Research, 1992, 593, 221-225.	2.2	22
56	A Pilot Study of Memantine Effects on Protracted Withdrawal (Syndrome of Anhedonia) in Heroin Addicts. Addictive Disorders and Their Treatment, 2002, 1, 143-146.	0.5	20
57	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. Drug and Alcohol Dependence, 2013, 132, 74-80.	3.2	20
58	Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment) randomized controlled trial. Addiction, 2008, 103, 1474-1483.	3.3	19
59	Estradiol lowers intracranial self-stimulation thresholds and enhances cocaine facilitation of intracranial self-stimulation in rats. Hormones and Behavior, 2010, 58, 827-834.	2.1	19
60	Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. European Neuropsychopharmacology, 2000, 10, 447-454.	0.7	18
61	A comparison of the effects of individual organic solvents and their mixture on brain stimulation reward. Pharmacology Biochemistry and Behavior, 1994, 48, 661-664.	2.9	16
62	Co-housing in a stable hierarchical group is not aversive for dominant and subordinate individuals. Neuroscience and Behavioral Physiology, 2000, 30, 195-200.	0.4	16
63	Effects of morphine and cocaine in mice with stable high aggressive and nonaggressive behavioral strategy. Pharmacology Biochemistry and Behavior, 2004, 77, 235-243.	2.9	16
64	A highly selective $\hat{l}^{o}$ -opioid receptor agonist with low addictive potential and dependence liability. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3609-3613.	2.2	16
65	Involvement of endogenous digitalis-like factors involuntary selection of alcohol by rats. Life Sciences, 1999, 64, PL219-PL225.	4.3	15
66	Morphine-induced Straub tail reaction in mice treated with serotonergic compounds. European Journal of Pharmacology, 2016, 791, 1-7.	3.5	14
67	Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV,the, 2019, 6, e221-e229.	4.7	13
68	Marinobufagenin (MBG) suppression of ethanol-seeking behavior is associated with inhibition of brain cortex Na/K-ATPase in mice. European Neuropsychopharmacology, 2002, 12, 217-223.	0.7	12
69	Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behavioural Pharmacology, 2006, 17, 295-302.	1.7	12
70	Effects of alcohol withdrawal on cardiovascular system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 550-553.	4.8	12
71	Differences in the consumption rates and regulatory barriers to the accessibility of strong opioid analgesics in Israel and St. Petersburg. European Journal of Clinical Pharmacology, 2012, 68, 89-95.	1.9	12
72	Behavioral analysis of the saccharin deprivation effect in rats Behavioral Neuroscience, 2002, 116, 747-756.	1.2	11

#	Article	IF	CITATIONS
73	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. AIDS and Behavior, 2008, 12, 662-669.	2.7	11
74	Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. European Journal of Pharmacology, 2008, 591, 164-170.	3.5	11
75	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Molecular Psychiatry, 2019, 24, 1099-1111.	7.9	11
76	The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. Cellular and Molecular Neurobiology, 2020, 40, 215-228.	3.3	10
77	NMDA receptor antagonists prevent conditioned activation of intracranial self-stimulation in rats. European Journal of Pharmacology, 1997, 326, 109-112.	3.5	9
78	Prevention of Suicide by Naltrexone in a Recently Detoxified Heroin Addict. European Addiction Research, 2001, 7, 87-88.	2.4	9
79	Addiction treatment in Russia. Lancet, The, 2010, 376, 1145.	13.7	9
80	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. AIDS and Behavior, 2015, 19, 1089-1097.	2.7	9
81	Systems of reinforcement and drug dependence. Drug and Alcohol Dependence, 1982, 10, 295-301.	3.2	8
82	Endogenous bufadienolide mediates pressor response to ethanol withdrawal in rats. European Neuropsychopharmacology, 2008, 18, 74-77.	0.7	7
83	Binge Drinking and Unsafe Sex: A Study of Narcology Hospital Patients from St. Petersburg, Russia. Substance Abuse, 2009, 30, 213-222.	2.3	7
84	Altered Cardiovascular Responses to Nitrosorbide in Alcohol Withdrawal. Neuropsychobiology, 2003, 48, 124-130.	1.9	6
85	Determination of Buprenorphine and Naloxone in Patient Blood Plasma Using HPLC-MS. Pharmaceutical Chemistry Journal, 2015, 48, 690-695.	0.8	6
86	Effects of Verapamil, an Antagonist of L-Type Calcium Channels, on Cardiovascular Symptoms in Alcohol Withdrawal. Neuropsychobiology, 2008, 58, 123-127.	1.9	5
87	Interaction of Blockers of Ionotropic NMDA Receptors and Metabotropic Glutamate Receptors in a Working Memory Test in Rats. Neuroscience and Behavioral Physiology, 2010, 40, 807-811.	0.4	5
88	Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia. Drug and Alcohol Dependence, 2017, 172, 60-65.	3.2	5
89	mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?. Psychopharmacology, 2017, 234, 1333-1345.	3.1	5
90	Pain and Risk Behaviors Among HIV-Infected Persons in St. Petersburg, Russia. AIDS and Behavior, 2017, 21, 1775-1781.	2.7	4

#	Article	IF	CITATIONS
91	Stimulation-produced analgesia under repeated morphine treatment in rats. Pharmacology Biochemistry and Behavior, 1986, 25, 533-536.	2.9	3
92	Subchronic morphine increases amphetamine-induced potentiation of brain stimulation reward: reversal by DNQX. European Neuropsychopharmacology, 1995, 5, 89-93.	0.7	3
93	Cardiovascular effects of propranolol in patients with alcohol dependence during withdrawal. International Journal of Psychophysiology, 2007, 66, 225-230.	1.0	3
94	Effects of the NMDA receptor antagonist, d -CPPene, on sensitization to the operant decrement produced by naloxone in morphine-treated rats. Behavioural Pharmacology, 2001, 12, 135-142.	1.7	3
95	The reinforcing but nonanalgesic action of opioid stimulation of the ventral tegmental area. Bulletin of Experimental Biology and Medicine, 1986, 102, 1065-1068.	0.8	2
96	Behavioral effects of MK-801 in morphine-dependent and non-dependent mice. Life Sciences, 1995, 58, PL55-PL61.	4.3	2
97	Effect of kinurenic acid on the acquisition of intravenous morphine self-administration habit by rats. Bulletin of Experimental Biology and Medicine, 1996, 122, 698-700.	0.8	2
98	Antagonist Models for Relapse Prevention and Reducing HIV Risk. Journal of NeuroImmune Pharmacology, 2016, 11, 401-407.	4.1	2
99	Motivational properties of hypothalamic stimulation in cats. Bulletin of Experimental Biology and Medicine, 1973, 75, 233-235.	0.8	1
100	Hypothalamic self-stimulation in morphine-dependent rats during the abstinence syndrome. Bulletin of Experimental Biology and Medicine, 1978, 85, 321-324.	0.8	1
101	Action of naloxone on emotionally positive and antinociceptive effects of hypothalamic stimulation in rats. Bulletin of Experimental Biology and Medicine, 1979, 88, 1306-1309.	0.8	1
102	Calcium entry blockers and drug addiction. European Neuropsychopharmacology, 1993, 3, 220-221.	0.7	1
103	Classical conditioning of electrical self-stimulation of ventral tegmental area to brief visual stimuli in rats. Journal of Neuroscience Methods, 1996, 70, 1-4.	2.5	1
104	Nifedipine but not verapamil inhibits subjective effects of i.v. morphine in opiate-dependent patients. Addiction Biology, 1998, 3, 345-351.	2.6	1
105	Decrement in Operant Performance Produced by NMDA Receptor Antagonists in the Rat. Pharmacology Biochemistry and Behavior, 2000, 65, 611-620.	2.9	1
106	Analgesic effect of olipiphate on mouse model of chemical stimulation of peritoneum. Bulletin of Experimental Biology and Medicine, 2001, 131, 254-256.	0.8	1
107	Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 457-466.	3.0	1
108	Antagonist Treatment for Opioid Dependence: Promise and Hurdles. Current Treatment Options in Psychiatry, 2017, 4, 221-230.	1.9	1

#	Article	IF	Citations
109	Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity – compound RU-1205. Research Results in Pharmacology, 2020, 6, 59-65.	0.4	1
110	Use of Different Drug Formulations of Opioid Antagonist (Naltrexone) to Treat Opioid Dependence in Russia., 2015,, 521-530.		1
111	Hypothalamic self-stimulation under the chronic morphine treatment in the rat. Research Communications in Chemical Pathology and Pharmacology, 1977, 16, 707-19.	0.2	1
112	Effect of amphetamine and amytal sodium on blood serotonin level during stimulation of the hypothalamus. Bulletin of Experimental Biology and Medicine, 1971, 71, 523-524.	0.8	0
113	Comparison of the discriminative and analgesic effects of morphine. Bulletin of Experimental Biology and Medicine, 1984, 98, 1538-1540.	0.8	0
114	Influence on the emotional reinforcing systems of the brain as a method of pathogenetic therapy of alcoholism and toxicomania. Neuroscience and Behavioral Physiology, 1985, 15, 17-21.	0.4	0
115	Characteristics of brain and spinal cord opiate receptors in morphine-tolerant mice. Bulletin of Experimental Biology and Medicine, 1986, 102, 1209-1211.	0.8	0
116	Synthesis of 8-arylmorphones and 8-arylcodones and study of their analgesic activity. Pharmaceutical Chemistry Journal, 1989, 23, 44-46.	0.8	0
117	Neuroanatomical dissociation between reinforcing and analgesic effects of morphine. Bulletin of Experimental Biology and Medicine, 1989, 107, 53-55.	0.8	0
118	Tolerance for opiate analgesia: Complex effect of antagonists of receptors for excitatory amino acids. Bulletin of Experimental Biology and Medicine, 1994, 117, 491-493.	0.8	0
119	Studies of the analgesic activity of calcitonin fragments. Pharmaceutical Chemistry Journal, 1994, 28, 728-731.	0.8	0
120	Effect of isradipine, a dihydropyridine-calcium antagonist on I.V. self-administration of morphine in rats. Life Sciences, 1996, 59, PL159-PL164.	4.3	0
121	A sequencingâ€based survey of functional <i>APAF1</i> alleles in a large sample of individuals with affective illness and population controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 332-335.	1.7	0
122	Effects of Catechol-O-Methyltransferase Deficiency on the Reinforcing Effects of Cocaine (an) Tj ETQq0 0 0 rgBT	/Oyerlock	10 Tf 50 222
123	Infectious Diseases And Medical Complications Of Drug Abuse-Part 1: Naltrexone treatment and HIV risk reduction for heroin addiction: 10-years Penn-Pavlov experience. Canadian Journal of Addiction, 2009, 1, 27-28.	0.4	0
124	Role of the monoamines on positive and negative reinforcing systems of the brain. Annali Dell'Istituto Superiore Di Sanita, 1978, 14, 59-62.	0.4	0